Sort by
Items per page

Send to

Choose Destination

Search results

Items: 37


In Vitro Modulation of Endogenous Alternative Splicing Using Splice-Switching Antisense Oligonucleotides.

Park JE, Cartegni L.

Methods Mol Biol. 2017;1648:39-52. doi: 10.1007/978-1-4939-7204-3_4.


Alternatively spliced mu opioid receptor C termini impact the diverse actions of morphine.

Xu J, Lu Z, Narayan A, Le Rouzic VP, Xu M, Hunkele A, Brown TG, Hoefer WF, Rossi GC, Rice RC, Martínez-Rivera A, Rajadhyaksha AM, Cartegni L, Bassoni DL, Pasternak GW, Pan YX.

J Clin Invest. 2017 Apr 3;127(4):1561-1573. doi: 10.1172/JCI88760. Epub 2017 Mar 20.


Posttranscriptional Regulation and RNA Binding Proteins in Cancer Biology.

Ghigna C, Cartegni L, Jordan P, Paronetto MP.

Biomed Res Int. 2015;2015:897821. doi: 10.1155/2015/897821. Epub 2015 Jul 27. No abstract available.


A heroin addiction severity-associated intronic single nucleotide polymorphism modulates alternative pre-mRNA splicing of the μ opioid receptor gene OPRM1 via hnRNPH interactions.

Xu J, Lu Z, Xu M, Pan L, Deng Y, Xie X, Liu H, Ding S, Hurd YL, Pasternak GW, Klein RJ, Cartegni L, Zhou W, Pan YX.

J Neurosci. 2014 Aug 13;34(33):11048-66. doi: 10.1523/JNEUROSCI.3986-13.2014.


p53Ψ is a transcriptionally inactive p53 isoform able to reprogram cells toward a metastatic-like state.

Senturk S, Yao Z, Camiolo M, Stiles B, Rathod T, Walsh AM, Nemajerova A, Lazzara MJ, Altorki NK, Krainer A, Moll UM, Lowe SW, Cartegni L, Sordella R.

Proc Natl Acad Sci U S A. 2014 Aug 12;111(32):E3287-96. doi: 10.1073/pnas.1321640111. Epub 2014 Jul 29.


U1 snRNP-Dependent Suppression of Polyadenylation: Physiological Role and Therapeutic Opportunities in Cancer.

Spraggon L, Cartegni L.

Int J Cell Biol. 2013;2013:846510. doi: 10.1155/2013/846510. Epub 2013 Oct 27. Review.


Antisense Modulation of RNA Processing as a Therapeutic Approach in Cancer Therapy.

Spraggon L, Cartegni L.

Drug Discov Today Ther Strateg. 2013 Fall;10(3):e139-e148.


5' UTR control of native ERG and of Tmprss2:ERG variants activity in prostate cancer.

Zammarchi F, Boutsalis G, Cartegni L.

PLoS One. 2013;8(3):e49721. doi: 10.1371/journal.pone.0049721. Epub 2013 Mar 5.


New half-lives of r-process Zn and Ga isotopes measured with electromagnetic separation.

Madurga M, Surman R, Borzov IN, Grzywacz R, Rykaczewski KP, Gross CJ, Miller D, Stracener DW, Batchelder JC, Brewer NT, Cartegni L, Hamilton JH, Hwang JK, Liu SH, Ilyushkin SV, Jost C, Karny M, Korgul A, Królas W, Kuźniak A, Mazzocchi C, Mendez AJ 2nd, Miernik K, Padgett SW, Paulauskas SV, Ramayya AV, Winger JA, Wolińska-Cichocka M, Zganjar EF.

Phys Rev Lett. 2012 Sep 14;109(11):112501. Epub 2012 Sep 13.


Therapeutic hemoglobin levels after gene transfer in β-thalassemia mice and in hematopoietic cells of β-thalassemia and sickle cells disease patients.

Breda L, Casu C, Gardenghi S, Bianchi N, Cartegni L, Narla M, Yazdanbakhsh K, Musso M, Manwani D, Little J, Gardner LB, Kleinert DA, Prus E, Fibach E, Grady RW, Giardina PJ, Gambari R, Rivella S.

PLoS One. 2012;7(3):e32345. doi: 10.1371/journal.pone.0032345. Epub 2012 Mar 27.


Antitumorigenic potential of STAT3 alternative splicing modulation.

Zammarchi F, de Stanchina E, Bournazou E, Supakorndej T, Martires K, Riedel E, Corben AD, Bromberg JF, Cartegni L.

Proc Natl Acad Sci U S A. 2011 Oct 25;108(43):17779-84. doi: 10.1073/pnas.1108482108. Epub 2011 Oct 17.


Lifetime measurement of the 2(1)+ state in 20C.

Petri M, Fallon P, Macchiavelli AO, Paschalis S, Starosta K, Baugher T, Bazin D, Cartegni L, Clark RM, Crawford HL, Cromaz M, Dewald A, Gade A, Grinyer GF, Gros S, Hackstein M, Jeppesen HB, Lee IY, McDaniel S, Miller D, Rajabali MM, Ratkiewicz A, Rother W, Voss P, Walsh KA, Weisshaar D, Wiedeking M, Brown BA.

Phys Rev Lett. 2011 Sep 2;107(10):102501. Epub 2011 Aug 30.


Induction of antagonistic soluble decoy receptor tyrosine kinases by intronic polyA activation.

Vorlová S, Rocco G, Lefave CV, Jodelka FM, Hess K, Hastings ML, Henke E, Cartegni L.

Mol Cell. 2011 Sep 16;43(6):927-39. doi: 10.1016/j.molcel.2011.08.009.


Splicing factor hnRNPH drives an oncogenic splicing switch in gliomas.

Lefave CV, Squatrito M, Vorlova S, Rocco GL, Brennan CW, Holland EC, Pan YX, Cartegni L.

EMBO J. 2011 Sep 13;30(19):4084-97. doi: 10.1038/emboj.2011.259.


Orbital dependent nucleonic pairing in the lightest known isotopes of tin.

Darby IG, Grzywacz RK, Batchelder JC, Bingham CR, Cartegni L, Gross CJ, Hjorth-Jensen M, Joss DT, Liddick SN, Nazarewicz W, Padgett S, Page RD, Papenbrock T, Rajabali MM, Rotureau J, Rykaczewski KP.

Phys Rev Lett. 2010 Oct 15;105(16):162502. Epub 2010 Oct 12.


KLF4 is a novel candidate tumor suppressor gene in pancreatic ductal carcinoma.

Zammarchi F, Morelli M, Menicagli M, Di Cristofano C, Zavaglia K, Paolucci A, Campani D, Aretini P, Boggi U, Mosca F, Cavazzana A, Cartegni L, Bevilacqua G, Mazzanti CM.

Am J Pathol. 2011 Jan;178(1):361-72. doi: 10.1016/j.ajpath.2010.11.021. Epub 2010 Dec 23.


A preclinical approach for gene therapy of beta-thalassemia.

Breda L, Kleinert DA, Casu C, Casula L, Cartegni L, Fibach E, Mancini I, Giardina PJ, Gambari R, Rivella S.

Ann N Y Acad Sci. 2010 Aug;1202:134-40. doi: 10.1111/j.1749-6632.2010.05594.x.


Peptide-conjugated antisense oligonucleotides for targeted inhibition of a transcriptional regulator in vivo.

Henke E, Perk J, Vider J, de Candia P, Chin Y, Solit DB, Ponomarev V, Cartegni L, Manova K, Rosen N, Benezra R.

Nat Biotechnol. 2008 Jan;26(1):91-100. doi: 10.1038/nbt1366. Epub 2008 Jan 6.


Bombesin attenuates pre-mRNA splicing of glucocorticoid receptor by regulating the expression of serine-arginine protein p30c (SRp30c) in prostate cancer cells.

Zhu J, Gong JY, Goodman OB Jr, Cartegni L, Nanus DM, Shen R.

Biochim Biophys Acta. 2007 Jul;1773(7):1087-94. Epub 2007 May 3.


Seemingly neutral polymorphic variants may confer immunity to splicing-inactivating mutations: a synonymous SNP in exon 5 of MCAD protects from deleterious mutations in a flanking exonic splicing enhancer.

Nielsen KB, Sørensen S, Cartegni L, Corydon TJ, Doktor TK, Schroeder LD, Reinert LS, Elpeleg O, Krainer AR, Gregersen N, Kjems J, Andresen BS.

Am J Hum Genet. 2007 Mar;80(3):416-32. Epub 2007 Jan 18. Erratum in: Am J Hum Genet. 2007 Apr;80(4):816.


Determinants of exon 7 splicing in the spinal muscular atrophy genes, SMN1 and SMN2.

Cartegni L, Hastings ML, Calarco JA, de Stanchina E, Krainer AR.

Am J Hum Genet. 2006 Jan;78(1):63-77. Epub 2005 Nov 16.


Severe subacute GM2 gangliosidosis caused by an apparently silent HEXA mutation (V324V) that results in aberrant splicing and reduced HEXA mRNA.

Wicklow BA, Ivanovich JL, Plews MM, Salo TJ, Noetzel MJ, Lueder GT, Cartegni L, Kaback MM, Sandhoff K, Steiner RD, Triggs-Raine BL.

Am J Med Genet A. 2004 Jun 1;127A(2):158-66.


ESEfinder: A web resource to identify exonic splicing enhancers.

Cartegni L, Wang J, Zhu Z, Zhang MQ, Krainer AR.

Nucleic Acids Res. 2003 Jul 1;31(13):3568-71.


Correction of disease-associated exon skipping by synthetic exon-specific activators.

Cartegni L, Krainer AR.

Nat Struct Biol. 2003 Feb;10(2):120-5.


BRCA2 T2722R is a deleterious allele that causes exon skipping.

Fackenthal JD, Cartegni L, Krainer AR, Olopade OI.

Am J Hum Genet. 2002 Sep;71(3):625-31. Epub 2002 Jul 19. Erratum in: Am J Hum Genet. 2003 Dec;73(6):1477.


Listening to silence and understanding nonsense: exonic mutations that affect splicing.

Cartegni L, Chew SL, Krainer AR.

Nat Rev Genet. 2002 Apr;3(4):285-98. Review.


Two proteins essential for apolipoprotein B mRNA editing are expressed from a single gene through alternative splicing.

Dance GS, Sowden MP, Cartegni L, Cooper E, Krainer AR, Smith HC.

J Biol Chem. 2002 Apr 12;277(15):12703-9. Epub 2002 Jan 28.


A mechanism for exon skipping caused by nonsense or missense mutations in BRCA1 and other genes.

Liu HX, Cartegni L, Zhang MQ, Krainer AR.

Nat Genet. 2001 Jan;27(1):55-8.


Exonic splicing enhancer motif recognized by human SC35 under splicing conditions.

Liu HX, Chew SL, Cartegni L, Zhang MQ, Krainer AR.

Mol Cell Biol. 2000 Feb;20(3):1063-71.


A novel hnRNP protein (HAP/SAF-B) enters a subset of hnRNP complexes and relocates in nuclear granules in response to heat shock.

Weighardt F, Cobianchi F, Cartegni L, Chiodi I, Villa A, Riva S, Biamonti G.

J Cell Sci. 1999 May;112 ( Pt 10):1465-76.


Immunocytochemical detection of emerin within the nuclear matrix.

Squarzoni S, Sabatelli P, Ognibene A, Toniolo D, Cartegni L, Cobianchi F, Petrini S, Merlini L, Maraldi NM.

Neuromuscul Disord. 1998 Jun;8(5):338-44.


Oral exfoliative cytology for the non-invasive diagnosis in X-linked Emery-Dreifuss muscular dystrophy patients and carriers.

Sabatelli P, Squarzoni S, Petrini S, Capanni C, Ognibene A, Cartegni L, Cobianchi F, Merlini L, Toniolo D, Maraldi NM.

Neuromuscul Disord. 1998 Apr;8(2):67-71.


Heart-specific localization of emerin: new insights into Emery-Dreifuss muscular dystrophy.

Cartegni L, di Barletta MR, Barresi R, Squarzoni S, Sabatelli P, Maraldi N, Mora M, Di Blasi C, Cornelio F, Merlini L, Villa A, Cobianchi F, Toniolo D.

Hum Mol Genet. 1997 Dec;6(13):2257-64.


X-linked Emery-Dreifuss muscular dystrophy can be diagnosed from skin biopsy or blood sample.

Mora M, Cartegni L, Di Blasi C, Barresi R, Bione S, Raffaele di Barletta M, Morandi L, Merlini L, Nigro V, Politano L, Donati MA, Cornelio F, Cobianchi F, Toniolo D.

Ann Neurol. 1997 Aug;42(2):249-53.


hnRNP A1 selectively interacts through its Gly-rich domain with different RNA-binding proteins.

Cartegni L, Maconi M, Morandi E, Cobianchi F, Riva S, Biamonti G.

J Mol Biol. 1996 Jun 14;259(3):337-48.


Human hnRNP protein A1 gene expression. Structural and functional characterization of the promoter.

Biamonti G, Bassi MT, Cartegni L, Mechta F, Buvoli M, Cobianchi F, Riva S.

J Mol Biol. 1993 Mar 5;230(1):77-89.


Supplemental Content

Loading ...
Support Center